PT - JOURNAL ARTICLE AU - Paula Duarte-Guterman AU - Arianne Y. Albert AU - Cindy K. Barha AU - Liisa A.M. Galea AU - on behalf of the Alzheimer’s Disease Neuroimaging Initiative TI - Sex and APOE genotype influence Alzheimer’s disease tau neuropathology AID - 10.1101/2020.06.25.20139980 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.25.20139980 4099 - http://medrxiv.org/content/early/2020/06/26/2020.06.25.20139980.short 4100 - http://medrxiv.org/content/early/2020/06/26/2020.06.25.20139980.full AB - Alzheimer’s disease (AD) is characterised by severe cognitive decline and pathological changes in the brain (brain atrophy, hyperphosphorylation of tau, and deposition of toxic amyloid-beta protein). Females have worse neuropathology (AD biomarkers and brain atrophy rates) and cognitive decline than males, however biological sex can interact with diagnosis (mild cognitive impairment (MCI) or AD) and APOE genotype (number of ε4 alleles), although there are discrepancies between studies. Using the ADNI database, we analysed the effect of sex and APOE genotype (number of ε4 alleles) and sex and diagnosis (cognitively normal (CN), MCI, AD) on cognition (memory and executive function), hippocampal volume, CSF amyloid beta, CSF tau and ptau. More males were diagnosed with MCI but there was no sex difference in those diagnosed with AD, suggesting the progression from CN, MCI to AD may be sex-specific. We found, consistent with some studies, that females had higher levels of CSF tau-pathology that was disproportionately affected by APOE genotype compared to males. These results suggest that sex and APOE genotype effects on AD biomarkers may influence sex differences in incidence and progression of MCI and AD. We also detected sex differences in hippocampal volume but the direction was dependent on the method of correction. Females had better memory (including verbal) scores than males, which may suggest a delay in the onset of cognitive decline or diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementData collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding for this study was provided by a Canadian Institutes of Health Research (CHIR) grant to LAMG (PJT-148662). PDG is funded by the Alzheimer's Association of the USA and Brain Canada with the financial support of Health Canada through the Brain Canada Research Fund (AARF-17-529705). The views expressed herein do not necessarily represent the views of the Minister of Health or the Government of Canada. We thank Elizabeth Perez for help with data organization.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of British Columbia Office of Research Ethics Clinical Research Ethics BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).